spa fresh spa sanitiser, conditioner, clarifier & bacteriacide
spa industries global pty ltd - hydrogen peroxide - liquid - hydrogen peroxide ungrouped active 150.0 g/l - pool sanitiser - spa | outdoor spa | spa pools - bacteria
oncaspar
baxalta innovations gmbh - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,
reblozyl 25 mg
bristol, myers squibb (israel) limited, israel - luspatercept - powder for solution for injection - luspatercept 25 mg - luspatercept - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia
reblozyl 75 mg
bristol, myers squibb (israel) limited, israel - luspatercept - powder for solution for injection - luspatercept 75 mg - luspatercept - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia
xospata 40 mg
astellas pharma international b.v., israel - gilteritinib as fumarate - film coated tablets - gilteritinib as fumarate 40 mg - gilteritinib - xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation
xospata
astellas pharma europe b.v. - gilteritinib fumarate - leukemia, myeloid, acute - antineoplastic agents - xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation.,
spa protector spa lithium
pool ranger pty limited - refer to label - granular formulation - refer to label misc active 0.0 undefined - pool chlorine - spa | swimming pool | outdoor spa | spa pools - bacteria | protozoa | virus
hy-clor spa sanitiser spa tablets
hy-clor (australia) pty ltd - bromine present as bromo-chloro-dimethylhydantoin; chlorine present as bromo-chloro-dimethylhydantoin - tablet (inc. pellet, bolus, suppository, capsule) - bromine present as bromo-chloro-dimethylhydantoin mineral-bromine active 650.0 g/kg; chlorine present as bromo-chloro-dimethylhydantoin mineral-chlorine active 280.0 g/kg - pool algicide - indoor pool | spa | outdoor spa | spa pools - algae | bacteria
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets,cii- dextroamphetami
alvogen inc. - amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e), dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - amphetamine aspartate monohydrate 1.25 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. attention deficit hyperactivity disorder (adhd) a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental eff
rch monosodium l-aspartate 14mmol/10ml injection
the royal children's hospital - monosodium aspartate, quantity: 1.4 mmol/ml - injection, concentrated - excipient ingredients: water for injections - substrate for organ perfusion.